Viktor Svekolkin

Viktor Svekolkin

Auto-generated profile, based on publicly available information

Viktor Svekolkin

Boston Gene Corporation, Waltham, Massachusetts

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in Blood
Verified
Journal Article
Closed access
PDF file
ASAleksandr Sarachakov
Aleksandr Sarachakov
AVArina Varlamova
Arina Varlamova
VSViktor Svekolkin
Viktor Svekolkin
MPMargarita Polyakova
Margarita Polyakova
IVItzel Valencia
Itzel Valencia
SPSanjay Patel
Sanjay Patel
The spatial anatomy of hematopoiesis in the bone marrow (BM) has been extensively studied in mice and other preclinical models, but technical challenges have precluded a commensurate exploration in humans. Institutional pathology archives contain thousands of paraffinized BM core biopsy tissue specimens, providing a rich resource for studying the intact human BM topography in a variety of physiologic states. Thus, we developed an end-to-end pipeline involving multiparameter whole tissue staining, in situ imaging at single-cell resolution, and artificial intelligence–based digital whole slide image analysis and then applied it to a cohort of disease-free samples to survey alterations in the hematopoietic topography associated with aging. Our data indicate heterogeneity in marrow adipose tissue (MAT) content within each age group and an inverse correlation between MAT content and proportions of early myeloid and erythroid precursors, irrespective of age. We identify consistent endosteal and perivascular positioning of hematopoietic stem and progenitor cells (HSPCs) with medullary localization of more differentiated elements and, importantly, uncover new evidence of aging-associated changes in cellular and vascular morphologies, microarchitectural alterations suggestive of foci with increased lymphocytes, and diminution of a potentially active megakaryocytic niche. Overall, our findings suggest that there is topographic remodeling of human hematopoiesis associated with aging. More generally, we demonstrate the potential to deeply unravel the spatial biology of normal and pathologic human BM states using intact archival tissue specimens.

3 December 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
GHGlenn J. Hanna
Glenn J. Hanna
LOL. B. Oakley
L. B. Oakley
RSR. Shi
R. Shi
AOA. Oneill
A. Oneill
KSK. Y. Shin
K. Y. Shin
RHR. I. Haddad
R. I. Haddad
Purpose: Treatments after anti–PD-1 therapy for patients with recurrent, metastatic head and neck squamous cell carcinoma (HNSCC) are limited. Blocking PI3K signaling may lead to tumor immunomodulation and enhanced taxane sensitivity. This phase 2 trial evaluated dual, selective PI3Kδ/γ inhibition with docetaxel in patients with anti–PD-1 refractory recurrent, metastatic HNSCC. Patients and Methods: Patients received duvelisib (25 mg orally twice daily) with docetaxel (75 mg/m2 IV) every 21 days. The primary endpoint was overall response rate (RECIST v1.1), using a Simon two-stage design. Secondary endpoints were safety, progression-free survival, and overall survival, and exploratory endpoints were correlating immunologic and genomic parameters with outcomes. Results: From 11/1/21 to 10/10/23, 26 patients were enrolled (median age: 64, 96% men, 54% with human papillomavirus+ disease; primary site: 12 oropharynx, 11 oral cavity, and 3 larynx/hypopharynx. The best overall response rate was 19% [5/26; 95% confidence interval (CI), 6.8%–40.7%]. All were partial responses [median duration: 5.1 months (0.7–15.5)]; 46% (12/26) exhibited stable disease, and 32% (8/26) exhibited progression (1 unevaluable). Two patients remain on-treatment at data cutoff; 25% (6/24) came off for toxicity. Grade 3+ treatment-related adverse events were observed in 50% (13/26), most often elevated liver function tests (6, 23%). No deaths were treatment-related. At median follow-up of 6.5 months (0.7–26), median progression-free survival was 2.8 months (95% CI, 1.9–7.0); 17/26 patients had died. Median overall survival was 10.2 months (95% CI, 6.7–15.9), favoring human papillomavirus–negative patients. Greater tumor CD3+/CD8+ T-cell infiltration trended with improved outcomes. Conclusions: We report a favorable response rate when combining a selective PI3K pathway inhibitor and taxane in patients with anti–PD-1 refractory HNSCC.

5 June 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ARAndrea J. Radtke
Andrea J. Radtke
EPEkaterina Postovalova
Ekaterina Postovalova
AVArina Varlamova
Arina Varlamova
ABAlexander Bagaev
Alexander Bagaev
MSMaria Sorokina
Maria Sorokina
RGRonald N. Germain
Ronald N. Germain
SUMMARY: Reference atlases, molecular and spatial maps of mammalian tissues, are critical resources for discovery efforts and translational research. Their utility is dependent on operationalizing the resulting data by identifying cell types, histological patterns, and predictive biomarkers underlying health and disease. The human lymph node (LN) offers a compelling use case because of its importance in immunity, structural and cellular diversity, and neoplastic involvement. One hematological malignancy, follicular lymphoma (FL), evolves from developmentally blocked germinal center B cells residing in and trafficking through these tissues. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Here, we present an integrated portrait of healthy and FL LNs using multiple genomic and advanced imaging technologies. By leveraging the strengths of each platform, we identified several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk of FL patients.

17 February 2025
Verified
Other
Open access
GHGlenn J. Hanna
Glenn J. Hanna
LOL. B. Oakley
L. B. Oakley
RSR. Shi
R. Shi
AOA. Oneill
A. Oneill
KSK. Y. Shin
K. Y. Shin
RHR. I. Haddad
R. I. Haddad
Supplemental Table 7. Correlating pre-treatment tumor immune cell parameters with outcomes (N=18).

17 February 2025
Verified
Other
Open access
GHGlenn J. Hanna
Glenn J. Hanna
LOL. B. Oakley
L. B. Oakley
RSR. Shi
R. Shi
AOA. Oneill
A. Oneill
KSK. Y. Shin
K. Y. Shin
RHR. I. Haddad
R. I. Haddad
Supplemental Table 4. Univariate odds ratio and 95% CI for logistic regression models for predictors of response.

17 February 2025
Verified
Other
Open access
GHGlenn J. Hanna
Glenn J. Hanna
LOL. B. Oakley
L. B. Oakley
RSR. Shi
R. Shi
AOA. Oneill
A. Oneill
KSK. Y. Shin
K. Y. Shin
RHR. I. Haddad
R. I. Haddad
Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.